Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer

Gene Therapy

Volumn 12, Issue 3, 2005, Pages 272-280

  Scholz, I V ^a   Cengic, N ^a   Baker, C H ^b   Harrington, K J ^b   Maletz, K ^a   Bergert, E R ^b   Vile, R ^b   Goke B ^a   Morris, J C ^b   Spitzweg, C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

CEA promoter; Colon cancer; Radioiodine therapy; Sodium iodide symporter; Tissue specific expression

Indexed keywords

ADENOVIRUS VECTOR; CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; RADIOACTIVE IODINE; SODIUM IODIDE SYMPORTER;

ANTIGEN EXPRESSION; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CELL STRAIN HCT116; CLONOGENIC ASSAY; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEASIBILITY STUDY; GENE TARGETING; GENE TRANSFER; GENETIC STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING;

ADENOVIRIDAE;

EID: 13544264755     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302410     Document Type: Article

References (44)

1. Carrasco N. Iodide transport in the thyroid gland. Biochem Biophys Acta 1993; 1154: 65-82.
2. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-460.
3. Smanik PA et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996; 226: 339-345.
4. Smanik PA et al. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997; 138: 3555-3558.
5. Mazzaferri EL. Carcinoma of follicular epithelium: radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD (eds). The Thyroid: A Fundamental and Clinical Text, 7th edn. Lippincott, Raven: Philadelphia, 1996, pp 922-945.
6. Spitzweg C et al. The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001; 86: 3327-3335.
7. Dingli D, Russell SJ, Morris JC. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 2003; 90: 1079-1086.
8. Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin Oncol 1996; 23: 154-158.
9. Spitzweg C et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136-2141.
10. Spitzweg C et al. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 2000; 60: 6526-6530.
11. Spitzweg C et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531.
12. Okabe S, Arai T, Yamashita H, Sugihara K. Adenovirus-mediated prodrug-enzyme therapy for CEA-producing colorectal cancer cells. J Cancer Res Clin Oncol 2003; 129: 367-373.
13. Ueno M et al. Tumor-specific chemo-radio-gene therapy for colorectal cancer cells using adenovirus vector expressing the cytosine deaminase gene. Anticancer Res 2001; 21: 2601-2608.
14. Konishi F et al. Transcriptionally targeted in vivo gene therapy for carcinoembryonic antigen-producing adenocarcinoma. Hiroshima J Med Sci 1999; 48: 79-89.
15. Cao GW et al. Gene therapy for human colorectal carcinoma using human CEA promoter controlled bacterial ADP-ribosylating toxin genes human CEA: PEA & DTA gene transfer. World J Gastroenterol 1998; 4: 388-391.
16. Shen LZ et al. Specific CEA-producing colorectal carcinoma cell killing with recombinant adenoviral vector containing cytosine deaminase gene. World J Gastroenterol 2002; 8: 270-275.
17. Midgley R, Kerr DJ. Seminar in colorectal cancer. Lancet 1999; 353: 391-399.
18. Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Gene therapy strategies for colon cancer. Mol Med Today 2000; 6: 82-87.
19. - symporter gene. Endocrinology 1997; 138: 4493-4496.
20. - symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Therapy 2000; 7: 740-749.
21. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661-668.
22. Boland A et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-3492.
23. Smit JWA et al. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid 2000; 10: 939-943.
24. Smit JW et al. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 2002; 87: 1247-1253.
25. - symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41: 1898-1904.
26. Carlin S et al. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000; 7: 1529-1536.
27. Haberkorn U et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001; 42: 317-325.
28. La Perle KMD et al. In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 2001; 50: 170-178.
29. Schipper ML et al. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. Cancer Res 2003; 63: 1333-1338.
30. Dingli D et al. Genetically targeted radiotherapy for multiple myeloma. Blood 2003; 102: 489-496.
31. Cleutjens KBJM et al. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997; 11: 1256-1265.
32. Dannull J, Belldegrun AS. Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br J Urol 1997; 79: 97-103.
33. Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Therapy 1996; 3: 845-852.
34. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462.
35. Cao G et al. Comparison of carcinoembryonic antigen promoter regions isolated from human colorectal carcinoma and normal adjacent mucosa to induce strong tumor-selective gene expression. Int J Cancer 1998; 78: 242-247.
36. Schrewe H et al. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol Cell Biol 1990; 10 2738-2748.
37. Hauck W, Stanners CP. Transcriptional regulation of the carcinoembryonic antigen gene. J Biol Chem 1995; 270: 3602-3610.
38. Willcocks TC, Craig IW. Characterization of the genomic organization of human carcinoembryonic antigen (CEA): comparison with other family members and sequence analysis of 5′ controlling region. Genomics 1990; 8: 492-500.
39. Fichera A, Michelassi F, Arenas RB. Selective expression of carcinoembryonic antigen promoter in cancer cell lines. Dis Colon Rectum 1998; 41: 747-754.
40. Mitrofanova E et al. Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional spheroids. Anticancer Res 2003; 23: 2397-2404.
41. Weiss SJ, Philip NJ, Grollmann EF. Iodine transport in a continuous line of cultured cells from rat thyroid. Endocrinology 1984; 114: 1090-1098.
42. Urabe M et al. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991; 129: 807-814.
43. - symport activity is present in membrane vesicles from thyrotropin-deprived non-I-transporting cultured thyroid cells. Proc Natl Acad Sci USA 1994; 91: 3789-3793.
44. Castro MR et al. Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol 1999; 163: 495-504.